
==== Front
Clin Hematol Int
Clin Hematol Int
3084
Clinical Hematology International
2590-0048
SAABRON PRESS Website: Clinical Hematology International

39071177
121430
10.46989/001c.121430
Case Study
SARS-CoV2 is not just infection but a culprit of donor graft failure post-allogeneic stem cell transplant
Park Yoojin Writing – original draft 1 2
Park Silvia 2 3
Chinratanalab Wichai Writing – review & editing 2 4 5
Savani Bipin Writing – review & editing 2 4 5
Kassim Adetola Writing – review & editing 2 4 5
Douds Jonathan J Visualization Writing – review & editing 6
Sengsayadeth Salyka Conceptualization Writing – review & editing 2 4 5
https://orcid.org/0000-0002-5182-3870
Kim Tae Kon Conceptualization Writing – original draft Writing – review & editing 2 4 5
1 Duke University https://ror.org/00py81415
2 Medicine Vanderbilt University Medical Center https://ror.org/05dq2gs74
3 Department of Hematology The Catholic University of Korea
4 Vanderbilt-Ingram Cancer Center https://ror.org/02rjj2m04
5 VA Tennessee Valley Healthcare System https://ror.org/01c9rqr26
6 Department of Pathology, Microbiology, and Immunology
Contributed equally to this work

Corresponding author. Salyka Sengsayadeth, MD, salyka.sengsayadeth@vumc.org
Corresponding author. Tae Kon Kim MD/PhD, 615-875-2453 tae.k.kim@vumc.org
26 7 2024
2024
6 3 3337
25 4 2024
7 6 2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

donor graft failure
SARS-CoV2
==== Body
pmcThe patient was a 74-year-old gentleman with intermediate risk acute myeloid leukemia, who achieved first complete remission (CR1) after treatment with venetoclax/decitabine, and underwent a reduced intensity conditioning (RIC) matched unrelated donor (MUD) allogeneic stem cell transplant (allo-SCT). His early post-transplant course had minimal complications. His day +30 bone marrow (BM) exam revealed complete remission and BM chimerism showed nearly 100% donor. Unfortunately, he sustained severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection at day +48, requiring inpatient hospitalization and systemic therapy with Nirmatrelvis/ritonavir (Paxlovid) and steroids. Two weeks after his initial diagnosis of SARS-CoV2, his counts were noted to be dropping. Repeat BM biopsy showed hypocellular marrow but chimerism remained at 100% donor (Figure 1). The patient required multiple transfusions. His counts improved modestly with systemic steroid, eltrombopag and G-CSF. His day-100 BM exam revealed significant hypocellularity but 100% donor chimerism. His pancytopenia continued to worsen, and his course was complicated by febrile neutropenia and bleeding. Eventually he expired at day +160 due to complications from severe pancytopenia.

237052 Figure 1. SARS-CoV2 infection suppresses bone marrow post-allogeneic stem cell transplant. Compared with day +30 post-SCT bone marrow, bone marrow biopsy after SARS-CoV2 infection revealed significantly low cellularity.

Recipients of allo-SCT are at high risk for viral infection due to delayed immune recovery and immune-suppressive therapy. One of the most significant causes of opportunistic viral infection post-HSCT is human cytomegalovirus infection (CMV), which is associated with an increased risk of graft failure and mortality.1,2 In addition to CMV, there have been reports of either primary or secondary graft failure or poor graft function caused by parainfluenza virus, herpes simplex virus type 1, and parvovirus B19 infection.3–5 However, the impact of SARS-CoV2 infection on allo-SCT recipients remains to be elucidated. SARS-CoV2 causes pneumonia that often results in poor clinical outcomes. especially in pre- or early post-engraftment phase.6 SARS-CoV2 can also lead to profound cytopenia and even graft failure in patients after allo-SCT.7,8 The case we report showed significant pancytopenia associated with hypoplastic marrow following SARS-CoV2 infection. As the patient experienced a decline in hematopoietic function after prior engraftment, but continued to maintain complete chimerism, this could be classified as poor graft function rather than secondary graft failure.9,10 Although we could not completely exclude other possibilities responsible for graft dysfunction, such as older age and unrelated donor, we believe that the viral infection, specifically COVID-19 in this case, may substantially contribute to the development of graft dysfunction given its sequential occurrence.

Several studies have reported that SARS-CoV2 induces BM suppression,11,12 manifested by pancytopenia, thrombocytopenia alone, or lymphopenia alone.12,13 Its etiology remains to be elucidated. SARS-CoV2-induced BM suppression may be associated with thrombosis, such as disseminated intravascular coagulation (DIC). Patients with severe SARS-CoV2 disease frequently develop thrombotic complications due to the hyperinflammatory response caused by the virus.14 In addition, hyper-inflammation is caused by excessive neutrophil infiltration and increased formation of neutrophil extracellular traps (NETs).15 Further, some metabolic conditions associated with states of chronic inflammation can increase neutrophil predisposition to form NETs.16 The components of NETs can also abnormally activate the coagulation pathway and participate in the formation of pathological thrombi that cause BM suppression.17

SARS-CoV2 induces the cytokine storm that leads to BM suppression.18 Vanderbeke et al (2021) report that neutrophils contribute to disease severity and local tissue damage by amplifying hyper-cytokinemia and forming NETs.19 Another cause of inflammation is the increased levels of inflammatory cytokines, including IL-1β, IL-2, IL-6, IL-10, IFN-γ, TNF-α, IFN-γ-inducible protein 10 (IP-10), granulocyte macrophage-colony stimulating factor (GM-CSF), and monocyte chemoattractant protein-1 (MCP-1).20 These cytokines correlate with the severity of SARS-CoV2.21,22 Specifically, increased IFN-γ results in BM failure by disrupting hematopoietic stem cell (HSC) differentiation and by driving hematopoietic collapse.23

SARS-CoV2 may dysregulate hematopoiesis that is associated with BM failure. Lymphoid-primed progenitor cells were dramatically depleted and the accumulation of immature granulocyte-monocyte progenitor cells were found in BM of severe SARS-CoV2 patients.11 It was shown that HSCs in these patients were mainly in the G1 phase and prone to apoptosis, with immune activation and anti-viral responses. Along with these findings, there was an up-regulation of transcription factors (such as SPI1, LMO4, ETS2, FLI1, and GATA2) that are important for HSCs or for the differentiation of multipotent progenitors.11 Severe SARS-CoV2 patients had a significantly low percentage of HSCs, common myeloid progenitors, and granulocyte-macrophage progenitors compared to non-severe cases.24

In addition, COVID-19 may cause hemophagocytic lymphohistiocytosis (HLH), which is associated with BM failure. HLH is an immune-mediated process characterized by an uncontrolled activation and disinhibition of cytotoxic T cells, macrophages, and natural killer (NK) cells.25 Recent studies noted high incidence of hemophagocytosis in BM and provided data to support evidence of secondary HLH in SARS-CoV2 patients.26,27 The clinical characteristics of SARS-CoV2 resemble secondary HLH, including high cytopenia, thrombocytopenia, and dyspnea.28 In HLH, the inability of NK and CD8+ cytotoxic T lymphocytes (CTLs) to provide critical negative feedback in response to an immunologic trigger leads to uncontrolled activation of CTLs and macrophages and initiation of a “cytokine storm”.25,29,30 At the initial phase of the severe infectious stage of SARS-CoV2, it is difficult to attribute inflammatory reactions solely to HLH versus SARS-CoV2 infection without other evidence, especially from BM biopsy.31 Therefore, conclusive pathophysiology behind post- SARS-CoV2 HLH is yet to be found.31

Certain viruses, such as parvovirus B19, may infect HSCs directly, causing changes in BM production. Parvovirus B19 infection can trigger an acute cessation of red blood cell production, leading to transient aplastic crisis, chronic red cell aplasia, hydrops fetalis, or congenital anemia.32 In persistent B19 infection, there is generally a decrease or absence of erythroid precursors, with sparing of other BM lineages.33 It is not known whether SARS-CoV2 infects HSCs directly.

In conclusion, SARS-CoV-2 infection leading to BM suppression is rare. However, we report a case of BM graft failure associated with SARS-CoV2. It would be difficult to demonstrate the causality of SARS-CoV2 infection with BM suppression in patients. While SARS-CoV2 specific T cells can be assessed using ex vivo studies (i.e. tetramer staining for SARS-CoV2 specific T cells, cytokine flow cytometry, multiplex immunoassays),34 cross-sectional assessment may limit the causality of SARS-CoA2 infection on BM suppression. Despite this limitation, SARS-CoV2 induced cytokine storm, dysregulated hematopoiesis, and HLH are all possible factors that affect the BM graft and can cause donor graft failure. Patients who receive allo-SCT are more prone to BM graft failure due to SARS-CoV2 infections, and should be carefully monitored for the early identification of BM suppression.

Authors’ Contribution

Writing – original draft: Yoojin Park (Equal), Tae Kon Kim (Equal). Writing – review & editing: Wichai Chinratanalab (Equal), Bipin Savani (Equal), Adetola Kassim (Equal), Jonathan J Douds (Equal), Salyka Sengsayadeth (Equal), Tae Kon Kim (Equal). Visualization: Jonathan J Douds (Lead). Conceptualization: Salyka Sengsayadeth (Equal), Tae Kon Kim (Equal).

Competing of Interest

TKK is a consultant for Agenus and Immunobiome but is irrelevant to this project.

Ethical Conduct Approval – Helsinki – IACUC

(for more information, read https://chi.scholasticahq.com/for-authors)

Not applicable.

Informed Consent

All authors and institutions have confirmed this manuscript for publication.

Data Availability Statement

All are available upon reasonable request.

Acknowledgments

This study was partially supported by an American Cancer Society Clinician Scientist Development Grant (CSDG-18-198-01), the American Cancer Society-Institutional Research Grant (ACS-IRG) IRG-22-145-62-04, Vanderbilt Ingram Cancer Center-Cancer Center Support Grant (CCSG).
==== Refs
Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation Blood Adv Kaito S. Nakajima Y. Hara K.. 2020
4 6 1051 1061 10.1182/bloodadvances.2019000814 10.1182/bloodadvances.2019000814 32191806
The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping Ann Hematol Wu X. Ma X. Song T. Liu J. Sun Y. Wu D. 2024
103 3 917 933 10.1007/s00277-023-05509-7 10.1007/s00277-023-05509-7 38227006
Secondary graft failure associated with parainfluenza virus infection following hematopoietic cell transplantation Bone Marrow Transplant Grewal S. S. van Burik J. A. H. Peters C. 2005
35 4 425 425 10.1038/sj.bmt.1704782 10.1038/sj.bmt.1704782 15640820
Primary Graft Failure Caused by Herpes Simplex Virus Type 1 Cornea Cockerham G. 2001
20 7 774 10.1097/00003226-200110000-00024 11588438
Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation Cancer Rep Rattani N. Matheny C. Eckrich M. J. Madden L. M. Quigg T. C. 2021
5 1 e1403 10.1002/cnr2.1403 10.1002/cnr2.1403
Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: Life-threatening Features Within the Early Post-engraftment Phase HemaSphere Oltolini C. Guidetti A. Ripa M.. 2020
4 4 e448 10.1097/HS9.0000000000000448 10.1097/HS9.0000000000000448
COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience Br J Haematol Lucchini G. Furness C. Lawson S.. 2021
194 4 e74 e77 10.1111/bjh.17547 10.1111/bjh.17547 34132400
Posthematopoietic stem cell transplant COVID-19 infection in a pediatric patient with IPEX syndrome Pediatr Blood Cancer Alicea Marrero M. M. Silio M. McQueen-Amaker K. Español M. Velez M. LeBlanc Z. 2021
68 1 e28578 10.1002/pbc.28578 10.1002/pbc.28578 32969118
Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation Blood Adv Prabahran A Koldej R Chee L Ritchie D 2022
6 6 1947 1959 10.1182/bloodadvances.2021004537 10.1182/bloodadvances.2021004537 34492685
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy Transplant Cell Ther Kharfan-Dabaja M. A. Kumar A. Ayala E.. 2021
27 8 642 649 10.1016/j.jtct.2021.04.007 34304802
Dysregulated hematopoiesis in bone marrow marks severe COVID-19 Cell Discov Wang X. Wen Y. Xie X.. 2021
7 1 60 10.1038/s41421-021-00296-9 10.1038/s41421-021-00296-9 34349096
Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist Am J Hematol Korompoki E. Gavriatopoulou M. Fotiou D. Ntanasis-Stathopoulos I. Dimopoulos M. A. Terpos E. 2022
97 1 119 128 10.1002/ajh.26384 34687462
COVID-19-associated pancytopenia can be self-limiting and does not necessarily warrant bone marrow biopsy for the purposes of SARS-CoV-2 diagnostics Ann Oncol Off J Eur Soc Med Oncol Hersby D. S. Do T. H. Gang A. O. Nielsen T. H. 2021
32 1 121 123 10.1016/j.annonc.2020.09.020 10.1016/j.annonc.2020.09.020
Pancytopenia Secondary to SARS-CoV-2 Infection-a Case Report SN Compr Clin Med Sharma N. Shukla R. Warrier R.. 2022
4 1 31 10.1007/s42399-021-01085-x 10.1007/s42399-021-01085-x 35036849
Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches BMB Rep Choi H. Shin E.C. 2022
55 1 11 19 10.5483/BMBRep.2022.55.1.152 10.5483/BMBRep.2022.55.1.152 34903319
Novel cell death program leads to neutrophil extracellular traps J Cell Biol Fuchs T. A. Abed U. Goosmann C.. 2007
176 2 231 241 10.1083/jcb.200606027 10.1083/jcb.200606027 17210947
Impact of Neutrophil Extracellular Traps on Thrombosis Formation: New Findings and Future Perspective Front Cell Infect Microbiol Zhou Y. Xu Z. Liu Z. 2022
12 910908 10.3389/fcimb.2022.910908 10.3389/fcimb.2022.910908 35711663
The Roles of Neutrophils in Cytokine Storms Viruses Chan L. Karimi N. Morovati S.. 2021
13 11 2318 10.3390/v13112318 10.3390/v13112318 34835125
Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity Nat Commun Vanderbeke L. Van Mol P. Van Herck Y.. 2021
12 1 4117 10.1038/s41467-021-24360-w 10.1038/s41467-021-24360-w 34226537
Cytokine Storm in COVID-19: Immunopathogenesis and Therapy Med Kaunas Lith Zanza C. Romenskaya T. Manetti A.C.. 2022
58 2 144 10.3390/medicina58020144 10.3390/medicina58020144
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet Lond Engl Huang C. Wang Y. Li X.. 2020
395 10223 497 506 10.1016/S0140-6736(20)30183-5 10.1016/S0140-6736(20)30183-5
[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia] Zhonghua Jie He He Hu Xi Za Zhi Zhonghua Jiehe He Huxi Zazhi Chin J Tuberc Respir Dis Chen L. Liu H.G. Liu W.. 2020
43 0 E005 10.3760/cma.j.issn.1001-0939.2020.0005 10.3760/cma.j.issn.1001-0939.2020.0005
The role of inflammation in hematopoiesis and bone marrow failure: What can we learn from mouse models? Front Immunol Wang J. Erlacher M. Fernandez-Orth J. 2022
13 951937 951937 10.3389/fimmu.2022.951937 10.3389/fimmu.2022.951937 36032161
Phenotypical changes of hematopoietic stem and progenitor cells in COVID-19 patients: Correlation with disease status Cent-Eur J Immunol Hussein H.A.M. Thabet A.A.A. Mohamed T.I.A.. 2023
48 2 97 110 10.5114/ceji.2023.129981 10.5114/ceji.2023.129981 37692025
Hemophagocytic Lymphohistiocytosis Annu Rev Pathol Al-Samkari H. Berliner N. 2018
13 27 49 10.1146/annurev-pathol-020117-043625 10.1146/annurev-pathol-020117-043625 28934563
Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore J Clin Pathol Núñez-Torrón C. Ferrer-Gómez A. Moreno Moreno E.. 2022
75 6 383 389 10.1136/jclinpath-2020-207337 10.1136/jclinpath-2020-207337 33722841
Bone Marrow and Peripheral Blood Findings in Patients Infected by SARS-CoV-2 Am J Clin Pathol Harris C.K. Hung Y.P. Nielsen G.P. Stone J.R. Ferry J.A. 2021
155 5 627 637 10.1093/ajcp/aqaa274 10.1093/ajcp/aqaa274 33502434
Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases? BMC Med Opoka-Winiarska V. Grywalska E. Roliński J. 2020
18 1 214 10.1186/s12916-020-01682-y 10.1186/s12916-020-01682-y 32664932
An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder Blood Jordan M. B. Hildeman D. Kappler J. Marrack P. 2004
104 3 735 743 10.1182/blood-2003-10-3413 10.1182/blood-2003-10-3413 15069016
Cytokine Storm N Engl J Med Fajgenbaum D.C. June C.H. 2020
383 23 2255 2273 10.1056/NEJMra2026131 10.1056/NEJMra2026131 33264547
Coronavirus Does It Again: Post-COVID-19 Hemophagocytic Lymphohistiocytosis (HLH) Cureus Jeyakanthan T. Ladel L. Khandpur B. Tan W. Y. Nasir S. A. 2023
15 2 e35275 10.7759/cureus.35275 10.7759/cureus.35275 36968874
Clinical presentations of parvovirus B19 infection Am Fam Physician Servey J. T. Reamy B. V. Hodge J. 2007
75 3 373 376 17304869
Parvoviruses and bone marrow failure Stem Cells Dayt Ohio Brown K. E. Young N. S. 1996
14 2 151 163 10.1002/stem.140151 10.1002/stem.140151
SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: Natural Infection and Response to Vaccine J Clin Immunol Gupta S. Agrawal S. Sandoval A. Su H. Tran M. Demirdag Y. 2022
42 5 914 922 10.1007/s10875-022-01256-y 10.1007/s10875-022-01256-y 35366743
